Loading...
•
Jun 30
Nuwellis Q2 2025 Earnings Report
Nuwellis reported Q2 2025 results marked by a revenue decline and wider net loss, impacted by sterilization vendor disruption and increased financial expenses.
Key Takeaways
Nuwellis generated $1.7 million in revenue during Q2 2025, down from $2.2 million YoY due to a temporary vendor issue. Gross margin declined to 55.5%. The company posted a net loss of $12.6 million and an operating loss of $2.9 million. Cash and cash equivalents stood at $4.45 million as of quarter-end.
Revenue decreased to $1.7 million from $2.2 million in Q2 2024 due to sterilization delays.
Gross margin dropped to 55.5%, impacted by under-absorption of overhead.
Net loss widened to $12.6 million or $(60.99) per share, driven by financing expenses.
Cash balance was $4.45 million, with no outstanding debt and a $5M capital raise completed.
Nuwellis
Nuwellis
Forward Guidance
Nuwellis is focused on expanding pediatric adoption and outpatient growth, while working to stabilize operations following temporary disruption.
Positive Outlook
- Added two new pediatric centers, bringing total to 47 using Aquadex.
- Raised $5 million in gross capital to support operations.
- Expanded IP with new patent on fluid bag design.
- Focused realignment targeting pediatric and cardiac surgery markets.
- Outsourced manufacturing transition executed to reduce costs long-term.
Challenges Ahead
- Temporary sterilization vendor issue disrupted product supply and revenue.
- Gross margin declined YoY due to fixed overhead under-absorption.
- Net loss widened to $12.6 million due to higher financing expenses.
- SG&A and R&D expenses remained flat or slightly increased.
- Revenue fell $0.5 million YoY despite operational efforts.